Closed-loop optogenetic targeting of PV interneurons to restore motor circuit inhibition and attenuate excitotoxicity-driven motor neuron degeneration in ALS

In AD, optogenetic PV interneuron activation restores theta-gamma coupling disrupted by amyloid-beta, preserving synaptic function. Analogously, in ALS, enhancing PV interneuron activity in motor cortex could reduce hyperexcitability and glutamatergic toxicity on motor neurons, potentially slowing degeneration. This predicts that PV-targeted optogenetic intervention will reduce motor neuron loss and improve motor performance in ALS mouse models.

Analogy rationale: Both AD and ALS involve circuit-level dysfunction contributing to neuronal loss; PV interneurons provide critical inhibitory control in both hippocampal (AD) and motor (ALS) circuits, making them viable therapeutic targets despite organ-level differences.

Disanalogies: AD pathology centers on amyloid-beta and hippocampal synaptic dysfunction, whereas ALS involves TDP-43/SOD1 aggregates and motor neuron degeneration; theta-gamma coupling may not have a direct motor circuit analog, and spinal cord accessibility poses technical challenges.

Falsifiable prediction: Optogenetic activation of PV interneurons in SOD1G93A mice will reduce motor cortex hyperexcitability (measured via in vivo electrophysiology) and delay motor neuron loss by >20% compared to controls at 90 days.

This hypothesis was generated from h-var-e95d2d1d86 in Alzheimer's disease — judge it on its own merits but acknowledge the source.